AUTHORS
Matthias M Mauschitz, Timo Verzijden, Alexander K Schuster, Hisham Elbaz, Norbert Pfeiffer, Anthony Khawaja, Robert N Luben, Paul J Foster, Franziska G Rauscher, Kerstin Wirkner, Toralf Kirsten, Jost B Jonas, Mukharram M Bikbov, Ruth Hogg, Tunde Peto, Audrey Cougnard-Grégoire, Geir Bertelsen, Maja Gran Erke, Fotis Topouzis, Dimitrios A Giannoulis, Caroline Brandl, Iris M Heid, Catherine P Creuzot-Garcher, Pierre-Henry Gabrielle, Hans-Werner Hense, Daniel Pauleikhoff, Patricia Barreto, Rita Coimbra, Stefano Piermarocchi, Vincent Daien, Frank G Holz, Cecile Delcourt, Robert P Finger, European Eye Epidemiology (E3) Consortium
Br J Ophthalmol. 2022 Nov 7:bjo-2022-321985. doi: 10.1136/bjo-2022-321985. Online ahead of print.
ABSTRACT
BACKGROUND/AIMS: To investigate the association of commonly used systemic medications with prevalent age-related macular degeneration (AMD) in the general population.
METHODS: We included 38 694 adults from 14 population-based and hospital-based studies from the European Eye Epidemiology consortium. We examined associations between the use of systemic medications and any prevalent AMD as well as any late AMD using multivariable logistic regression modelling per study and pooled results using random effects meta-analysis.
RESULTS: Between studies, mean age ranged from 61.5±7.1 to 82.6±3.8 years and prevalence ranged from 12.1% to 64.5% and from 0.5% to 35.5% for any and late AMD, respectively. In the meta-analysis of fully adjusted multivariable models, lipid-lowering drugs (LLD) and antidiabetic drugs were associated with lower prevalent any AMD (OR 0.85, 95% CI=0.79 to 0.91 and OR 0.78, 95% CI=0.66 to 0.91). We found no association with late AMD or with any other medication.
CONCLUSION: Our study indicates a potential beneficial effect of LLD and antidiabetic drug use on prevalence of AMD across multiple European cohorts. Our findings support the importance of metabolic processes in the multifactorial aetiology of AMD.
PMID:36344262 | DOI:10.1136/bjo-2022-321985
